The US Food and Drug Administration (FDA) has approved a new HIV drug that inhibits the virus’ ability to multiply and can be used with existing antiretroviral drugs.
The new drug, dolutegravir, is an integrase strand transfer inhibitor. It helps reduce HIV viral load by interfering with virus replication. It is approved for use in combination with other antiretroviral drugs in adults who are new to treatment or who have previously taken anti-HIV medications. However, the drug is only approved for use in children who are at least age 12 years, weigh at least 40 kg, and have never taken an integrase strand transfer inhibitor.
Kuehn BM. FDA Approves New HIV Drug. JAMA. 2013;310(12):1217. doi:10.1001/jama.2013.278508
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: